Top Tweets for #abbottIndia

🧵 Why $ABBOTTINDIA is one of India's most quietly compounding pharma stocks 👇 🏭 What They Do: Abbott India is the Indian arm of global healthcare giant Abbott Laboratories, specialising in branded generics, diagnostics, and nutritional products — with a strong focus on chronic disease management and a field force reaching 500,000+ doctors. Global R&D. Local execution. Unmatched doctor trust. 💊 📈 The Consistent Growth Machine: Q1 FY26: Revenue +11.6% YoY. PAT +11.5% YoY. Q2 FY26: Revenue +7.6% YoY. PAT +15.8% YoY. 9M FY26: Revenue +8.7% YoY. Net Profit +7.7% YoY to ₹1,157 Cr. Steady. Predictable. Quarter after quarter. 📊 💰 The Quality Metrics: ROE: 35.98%. ROCE: 47.87%. Debt: Zero. Operating margins: ~27%. 5-year stock return: 190%. Near-50% ROCE. Debt-free. High margins. This is an exceptional capital allocator. 💪 🔒 The Promoter Moat: Promoter holding: 74.99% — unchanged for multiple consecutive quarters. Parent Abbott Laboratories owns 75% and isn't selling. That's conviction. 🏦 💸 The Dividend Machine: Abbott declared a dividend of ₹475 per share for FY25. That's not a typo. ₹475 per share. Consistent, generous, and growing. 🎁 🚀 FUTURE GROWTH TRIGGERS: Trigger 1 — India Pharma Market $130 Bn by 2030: The Indian pharmaceutical industry is forecast to reach $130 billion by 2030 — from ~$50 billion today. Abbott is positioned right at the heart of this secular expansion with its chronic therapy focus. 📈 Trigger 2 — 200 Million+ Indians with Chronic Diseases: Chronic disease prevalence affects over 200 million Indians, fuelling demand for long-term therapies that Abbott reliably supplies. Chronic patients don't switch brands. Abbott's prescriptions are sticky for years. 🩺 Trigger 3 — FreeStyle Libre Next-Gen CGM Launch: Abbott introduced the next-gen FreeStyle Libre (2) Plus continuous glucose monitoring system in August 2025, expanding its diabetes management portfolio. India has 100 million+ diabetics. CGM penetration is still at single digits. The runway is enormous. 📡 Trigger 4 — New Heart Valve & Cardiac Devices: In January 2025, Abbott launched Navitor™ Vision, a new heart valve technology, followed by the TactiFlex™ Sensor Enabled™ Ablation Catheter — a global first introduced in India. Bringing world-first medical devices to India. Premium pricing. High margins. 🫀 Trigger 5 — Parent's India Growth: Double-Digit in Q4 CY25: Abbott Laboratories' global results confirmed double-digit growth in India in Q4 2025, with Established Pharmaceuticals in Key Emerging Markets growing 10.3% on a reported basis. The parent itself called India out as a key growth engine. 🌍 Trigger 6 — Goa Plant Efficiency Drive: Shifting manufacturing to its Goa plant is anticipated to bolster profit margins through operational efficiencies. Lower cost base + same premium pricing = margin expansion incoming. 🏭 Trigger 7 — India's Aging + Rising Income Demographics: The share of Indian households with annual incomes between $10,000–$35,000 is expected to nearly double from ~24% in 2021 to 46% by 2031. Wealthier Indians spend more on branded healthcare. Abbott is the premium default. 💰 Trigger 8 — Digital Transformation of Sales & Supply Chain: Abbott India's embrace of digital transformation in sales, marketing, and supply chain management is contributing to short-term gains and reducing stockouts. Tech-enabled pharma distribution = faster growth + stickier doctor relationships. 📲 Debt-free. 47% ROCE. 75% promoter holding. ₹475/share dividend. Global device launches in India. 200M chronic patients. $130 Bn pharma market by 2030. This isn't exciting. It's better — it's reliable. A compounder that quietly doubles every 4–5 years. #ABBOTTINDIA #AbbottIndia #NSE #Pharma #Healthcare #LargeCap #Compounder #IndianStocks #DYOR ⚠️ Disclaimer: Educational purposes only. Not investment advice. Always DYOR. Markets carry risk.